1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > VG Life Sciences, Inc. - Product Pipeline Review - 2015

VG Life Sciences, Inc. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 27 pages

VG Life Sciences, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘VG Life Sciences, Inc. - Product Pipeline Review - 2015’, provides an overview of the VG Life Sciences, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of VG Life Sciences, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of VG Life Sciences, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of VG Life Sciences, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the VG Life Sciences, Inc.’s pipeline products

Reasons to buy

- Evaluate VG Life Sciences, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of VG Life Sciences, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the VG Life Sciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of VG Life Sciences, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of VG Life Sciences, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of VG Life Sciences, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

VG Life Sciences, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
VG Life Sciences, Inc. Snapshot 5
VG Life Sciences, Inc. Overview 5
Key Information 5
Key Facts 5
VG Life Sciences, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
VG Life Sciences, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
VG Life Sciences, Inc. - Pipeline Products Glance 11
VG Life Sciences, Inc. - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
VG Life Sciences, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
VG Life Sciences, Inc. - Drug Profiles 14
hydroxychloroquine + sorafenib tosylate 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
VG-1177 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Peptide for Inflammatory Bowel Disease 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
VG Life Sciences, Inc. - Pipeline Analysis 18
VG Life Sciences, Inc. - Pipeline Products by Target 18
VG Life Sciences, Inc. - Pipeline Products by Route of Administration 19
VG Life Sciences, Inc. - Pipeline Products by Molecule Type 20
VG Life Sciences, Inc. - Pipeline Products by Mechanism of Action 21
VG Life Sciences, Inc. - Recent Pipeline Updates 22
VG Life Sciences, Inc. - Dormant Projects 24
VG Life Sciences, Inc. - Locations And Subsidiaries 25
Head Office 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 26
Disclaimer 27

List of Tables
VG Life Sciences, Inc., Key Information 5
VG Life Sciences, Inc., Key Facts 5
VG Life Sciences, Inc. - Pipeline by Indication, 2015 7
VG Life Sciences, Inc. - Pipeline by Stage of Development, 2015 8
VG Life Sciences, Inc. - Monotherapy Products in Pipeline, 2015 9
VG Life Sciences, Inc. - Combination Treatment Modalities in Pipeline, 2015 10
VG Life Sciences, Inc. - Phase I, 2015 11
VG Life Sciences, Inc. - Preclinical, 2015 12
VG Life Sciences, Inc. - Discovery, 2015 13
VG Life Sciences, Inc. - Pipeline by Target, 2015 18
VG Life Sciences, Inc. - Pipeline by Route of Administration, 2015 19
VG Life Sciences, Inc. - Pipeline by Molecule Type, 2015 20
VG Life Sciences, Inc. - Pipeline Products by Mechanism of Action, 2015 21
VG Life Sciences, Inc. - Recent Pipeline Updates, 2015 22
VG Life Sciences, Inc. - Dormant Developmental Projects,2015 24

List of Figures
VG Life Sciences, Inc. - Pipeline by Top 10 Indication, 2015 7
VG Life Sciences, Inc. - Pipeline by Stage of Development, 2015 8
VG Life Sciences, Inc. - Monotherapy Products in Pipeline, 2015 9
VG Life Sciences, Inc. - Pipeline by Top 10 Target, 2015 18
VG Life Sciences, Inc. - Pipeline by Top 10 Route of Administration, 2015 19
VG Life Sciences, Inc. - Pipeline by Top 10 Molecule Type, 2015 20
VG Life Sciences, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.